References
Profiles of participating companies. BIO 2004: Annual International Convention. Business Forum: 6 Jun 2004
Jerini AG. Jerini Concludes its Icatibant Phase II Study in Hereditary Angioedema with Positive Results. Media Release: 26 Aug 2004. Available from URL: http://www.jerini.com
Jerini AG. Jerini Initiates Pivotal Registration Study for Icatibant in Hereditary Angioedema. Media Release: 8 Sep 2004. Available from URL: http://www.jerini.com
Jerini AG. Jerini Receives FDA Fast Track Designation for Icatibant in Hereditary Angioedema. Media Release: 22 Jul 2004. Available from URL: http://www.jerini.com
Jerini. Jerini Has Been Granted Orphan Drug Designation by U.S. FDA for Icatibant, JE049, to Treat Patients with Angioedema. Media Release: 18 Nov 2003. Available from URL: http://www.jerini.com
Proud D. Clinical application of kinin antagonists. Canadian Journal of Physiology and Pharmacology 72 (Suppl. 2): 19, 1994
Jerini. Jerini Announces Positive Results in a Subcutaneous Bioavailability Study for Icatibant. Media Release: 14 Apr 2004. Available from URL: http://www.jerini.com
Wirth KJ, Gehring D, Schölkens BA. Effect of Hoe 140 on bradykinin-induced bronchoconstriction in anesthetized guinea pigs. American Review of Respiratory Disease 148: 702–706, Sep 1993
Wirth KJ, Gehring D, Schölkens BA. Effect of HOE 140 on bradykinin-induced bronchoconstriction in anaesthetised guinea pigs. Naunyn-Schmiedeberg’s Archives of Pharmacology 344 (Suppl. 2): R141, 1991
Jerini. Jerini’s Bradykinin Antagonist Icatibant Shows Promise in Treatment of Refractory Ascites in Liver Cirrhosis in a Phase II Study. Media Release: 2 Dec 2003. Available from URL: http://www.jerini.com
Sun W, Wainwright CL. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo. Coronary Artery Disease 5: 541–550, Jun 1994
Gaudron P, Hu K, Zdrojewski T, et al. AT1-receptor blocker versus angiotensin converting enzyme inhibitor in acute myocardial Role of dosage and bradykinin on remodelling, hemodynamics and mortality in the rat model. Journal of the American College of Cardiology 31 (Suppl. 2A): 311, Feb 1998
Proud D, Reynolds CJ, Broomfield J. Bradykinin effects in guinea pig tracheal epithelial cells are mediated through a gB2 kinin receptor and can be inhibited by the selective antagonist Hoe 140. Journal of Pharmacology and Experimental Therapeutics 264: 1124–1131, Mar 1993
Hock FJ, Wirth K, Albus U. Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. British Journal of Pharmacology 102: 769–773, Mar 1991
Rhaleb N-E, Rouissi N, Jukic D. Pharmacological characterization of a new highly potent ß2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin). European Journal of Pharmacology 210: 115–120, 14 Jan 1992
Félétou M, Germain M, Thurieau C. Agonistic and antagonistic properties of the bradykinin ß2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. British Journal of Pharmacology 112: 683–689, Jun 1994
Sakamoto T, Sun J, Barnes PJ, et al. Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig. European Journal of Pharmacology 251: 137–142, 14 Jan 1994
Sakamoto T, Elwood W, Barnes PJ. Evaluation of a bradykinin antagonist (HOE 140) against bradykinin and platelet activating factor induced airway responses in the guinea pig. Thorax 47: 241P, Mar 1992
Sakamoto T, Elwood W, Barnes PJ, et al. Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet- activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. European Journal of Pharmacology 213: 367–373, 31 Mar 1992
Sakamoto T, Elwood W, Barnes PJ. Effect of a novel bradykinin antagonist (HOE140) against bradykinin, platelet activating factor, sodium metabisulfite and allergen induced airway responses in the guinea pig. American Review of Respiratory Disease 145: A859, Apr 1992
Wirth K, Hock FJ, Albus U. Hoe 140, a new potent and long acting bradykinin-antagonist: in vivo studies. British Journal of Pharmacology 102: 774–777, Mar 1991
Damas J, Remacle-Volon G. Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat. European Journal of Pharmacology 211: 81–86, 28 Jan 1992
Featherstone RL, Parry JE, Church MK. The effects of kinin antagonism with HOE 140 on the response of guinea-pigs to allergen. Clinical and Experimental Allergy 23 (Suppl. 1): 32, Feb 1993
Austin CE, Foreman JC, Scadding GK. Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. British Journal of Pharmacology 111: 969–971, Apr 1994
Jerini AG. Jerini Announces Positive Phase II Study Results with Icatibant for the Treatment of Hereditary Angioedema. Media Release: 13 Jan 2004. Available from: URL: http:// www.jerini.com
Avery J, Barber C. A topical bradykinin antagonist first clinical trial of icatibant nasal spray in seasonal allergic rhinitis. Allergy and Clinical Immunology News (Suppl. 2): 415, 1994
Rights and permissions
About this article
Cite this article
Icatibant. Drugs R D 5, 343–348 (2004). https://doi.org/10.2165/00126839-200405060-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200405060-00006